Provided by Tiger Trade Technology Pte. Ltd.

Nuvectis Pharma, Inc.

22.49
-0.2900-1.27%
Post-market: 22.490.00000.00%16:10 EDT
Volume:107.05K
Turnover:2.42M
Market Cap:732.76M
PE:-17.24
High:23.02
Open:22.09
Low:22.01
Close:22.78
52wk High:29.28
52wk Low:5.55
Shares:32.58M
Float Shares:21.23M
Volume Ratio:0.72
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3045
EPS(LYR):-1.3236
ROE:-214.58%
ROA:-73.07%
PB:80.68
PE(LYR):-16.99

Loading ...

Roth MKM Remains a Buy on Nuvectis Pharma (NVCT)

TIPRANKS
·
Jun 23

Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending

Benzinga_recent_news
·
Jun 23

Haisco Pharmaceutical Group Enters Licensing Agreement with Nuvectis for Two Drug Candidates

Stock News
·
Jun 23

Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital

TIPRANKS
·
Jun 23

Nuvectis Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 22

Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright

TIPRANKS
·
Jun 22

Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets

TIPRANKS
·
Jun 22

Nuvectis Expands Pipeline With 2-Drug Licensing Deal From Haisco

MT Newswires Live
·
Jun 22

BUZZ-Nuvectis rises as it secures two experimental drugs in licensing deal

Reuters
·
Jun 22

Nuvectis Pharma announces license agreement with Haisco for two compounds

TIPRANKS
·
Jun 22

Nuvectis licenses ex-China rights to Haisco’s NXP100, NXP200 in deal worth up to USD 1.42 billion

Reuters
·
Jun 22

Nuvectis Pharma Inc: Haisco Also Retains Rights for Nxp100 in India and Certain Southeast Asia Territories

THOMSON REUTERS
·
Jun 22

Nuvectis: Haisco to Receive Upfront, Near-Term Payments up to $40 Mln, Eligible to Receive up to $1.421Bn in Additional Milestones, Tiered Royalties

THOMSON REUTERS
·
Jun 22

Nuvectis Pharma - Agreement Subject to Financing Conditions Requiring Nuvectis to Ensure Sufficient Capital

THOMSON REUTERS
·
Jun 22

Nuvectis Pharma - Expands Pipeline With Nxp100 and Nxp200 in-Licensing

THOMSON REUTERS
·
Jun 22

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights With Haisco Pharmaceutical Group for Two Potentially Best-in Class Clinical-Stage Compounds

THOMSON REUTERS
·
Jun 22

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

GlobeNewswire
·
Jun 22

Nuvectis Shareholders Approve Director Election and Auditor Ratification

TIPRANKS
·
Jun 13

Nuvectis Pharma shareholders approve auditor ratification at annual meeting

Reuters
·
Jun 13

Nuvectis Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 13